BSD Medical Corporation (NASDAQ:BSDM - News) reports that a Phase III study, which utilized the BSD-2000 Hyperthermia System, demonstrated that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after starting treatment if targeted heat therapy (hyperthermia) was added to their chemotherapy treatment. BSD's stock soared on the news to an intraday high of $4.77, a 154% gain from Monday's close.
Quotes/News/Charts
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment